Diabetic nephropathy future or investigational therapies

Diabetic nephropathy Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Diabetic nephropathy from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Diabetic nephropathy future or investigational therapies On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Diabetic nephropathy future or investigational therapies All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Diabetic nephropathy future or investigational therapies
CDC on Diabetic nephropathy future or investigational therapies
Diabetic nephropathy future or investigational therapies in the news
Blogs on Diabetic nephropathy future or investigational therapies
Directions to Hospitals Treating Diabetic nephropathy
Risk calculators and risk factors for Diabetic nephropathy future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aarti Narayan, M.B.B.S [2]

Future or Investigational Therapies

C-peptide, a by-product of insulin production, may provide new hope for patients sufering from diabetic nephropathy .